Travere Therapeutics
TVTX
60 hedge funds and large institutions have $165M invested in Travere Therapeutics in 2014 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 12 closing their positions.
1,054% more call options, than puts
Call options by funds: $2.47M | Put options by funds: $214K
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
2% more funds holding
Funds holding: 59 → 60 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $186M → $165M (-$20.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$18.1M |
| 2 |
BC
Broadfin Capital
New York
|
+$10.4M |
| 3 |
AC
Amici Capital
New York
|
+$4.65M |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$4.02M |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$3.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.84M |
| 2 |
LCM
LionEye Capital Management
New York
|
-$3.56M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.55M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.17M |
| 5 |
FNYS
First New York Securities
New York
|
-$974K |
TVTX Hedge Fund Activity: Q3 2014 in Review
60 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q3 2014, worth a combined $165M — down 11% from $186M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TVTX positions and 12 closed out — a net gain of 1 holder — while 24 added to existing stakes and 14 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $18.1M. The largest seller was Deutsche Bank, cutting an estimated $4.84M.
- 60 institutional investors held Travere Therapeutics (TVTX) as of Q3 2014, up from 59 in Q2 2014.
- Funds reported $165M of Travere Therapeutics stock for Q3 2014, down 11% quarter-over-quarter.
- 13 funds opened new Travere Therapeutics positions in Q3 2014 and 12 closed out, a net change of +1 holder.
- The largest Travere Therapeutics buyer in Q3 2014 was Consonance Capital Management, an estimated $18.1M added.
- The largest Travere Therapeutics seller in Q3 2014 was Deutsche Bank, an estimated $4.84M sold.
Based on aggregated 13F filings for Q3 2014.